


Lysaker, 20 April 2015

In accordance with the authorization granted by the Annual General Meeting
13(th) May 2014, the Board of Directors of PCI Biotech Holding ASA has awarded a
total of 93,500 options to key employees. Each option gives the right to
subscribe for or acquire one share per option (after PCI Biotech Holding ASA's
choice), at a strike price of NOK 12.53, equal to the volume weighted average
price (VWAP) for the last 5 days of trade prior to the grant date. The options
can be exercised with 1/3 of the options after one year, further 1/3 after two
years and the last third after three years. The options are lapsing in Q3 2020.

Of these options, 20,000 options were allotted to Ronny Skuggedal, CFO. After
the allocation, Ronny Skuggedal holds a total portfolio of 60,000 unexercised
options and 0 shares.

For more information, please contact:
Per Walday, CEO
E-mail: pw@pcibiotech.no
Mobile: 917 93 429

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1912484] 
    